{"id":28199,"date":"2026-03-01T07:31:13","date_gmt":"2026-03-01T07:31:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/28199\/"},"modified":"2026-03-01T07:31:13","modified_gmt":"2026-03-01T07:31:13","slug":"novo-nordisk-a-s-nvo-and-vivtex-corporation-announce-a-partnership-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/28199\/","title":{"rendered":"Novo Nordisk A\/S (NVO) and Vivtex Corporation Announce a Partnership"},"content":{"rendered":"\n

Novo Nordisk A\/S (NYSE:NVO<\/a>) is one of\u00a0the best cheap blue chip stocks to buy according to analysts<\/a>. Novo Nordisk A\/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. The terms of the agreement entail that Vivtex would license select oral drug-delivery technologies to Novo Nordisk A\/S (NYSE:NVO), with Vivtex eligible to receive upfront consideration, research funding, and milestone payments totalling up to $2.1 billion, and tiered royalties on future product sales. Vivtex\u2019s platform combines multiple proprietary gastrointestinal screening assays, drug-delivery technologies, and computational simulation and AI capabilities for the optimization of the oral delivery of biologic medicines.<\/p>\n

\"Berenberg Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating <\/p>\n

Management further reported that the primary goal of the collaboration is to allow the oral delivery of biologic drug candidates traditionally limited to injectable administration because of poor absorption in the gastrointestinal tract. The partnership thus brings together Novo Nordisk\u2019s (NYSE:NVO) expertise in peptide and protein therapeutics and Vivtex\u2019s proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics. Novo Nordisk A\/S (NYSE:NVO) further reported that following research and formulation selection, it will assume responsibility for regulatory activities, global development, manufacturing, and commercialization of any resulting products.<\/p>\n

Novo Nordisk A\/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.<\/p>\n

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 30 Stocks That Should Double in 3 Years<\/a>\u00a0and

Insider Monkey<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S (NYSE:NVO) is one of\u00a0the best cheap blue chip stocks to buy according to analysts. Novo…\n","protected":false},"author":2,"featured_media":8834,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[16353,16357,17567,6736,16358,272,16352,16355],"class_list":{"0":"post-28199","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-biologic-drug","9":"tag-biologic-medicines","10":"tag-blue-chip-stocks","11":"tag-diabetes-care","12":"tag-gastrointestinal-tract","13":"tag-novo-nordisk","14":"tag-oral-delivery","15":"tag-vivtex-corporation"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/28199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=28199"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/28199\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/8834"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=28199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=28199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=28199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}